Trial Profile
A Safety, Tolerability, and Pharmacokinetics Study of LY3451838 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Mar 2020
Price :
$35
*
At a glance
- Drugs LY-3451838 (Primary) ; LY-3451838 (Primary)
- Indications Migraine
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 02 Mar 2020 Status changed from active, no longer recruiting to completed.
- 03 Feb 2020 Planned End Date changed from 27 Feb 2020 to 26 Feb 2020.
- 03 Feb 2020 Planned primary completion date changed from 27 Feb 2020 to 26 Feb 2020.